StockMarketWire.com - GlaxoSmithKline said Thursday that its two-drug treatment for HIV, met its primary goal after demonstrating the ability to control HIV.

The studies met their primary endpoint for non-inferiority, a standard measure of HIV control, at Week 48, GSK’s majority owned ViiV Healthcare said.

The studies – GEMINI-1 and GEMINI-2 – were designed to evaluate the safety and efficacy of a two-drug regimen compared to a three-drug regimen.

'The safety results for the two-drug regimen of dolutegravir and lamivudine were consistent with the product labelling for the medicines,' the company added.

'The GEMINI studies demonstrate the potency, safety and tolerability of the dolutegravir plus lamivudine combination. They affirm our two-drug regimen strategy, and reinforce our belief that many patients can control their disease with two drugs instead of three or more,' said John C. Pottage, Jr., MD, Chief Scientific and Medical Officer of ViiV Healthcare.




Story provided by StockMarketWire.com